NCT00004248View on ClinicalTrials.gov

Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

June 30, 2000

Study Completion Date

May 31, 2001

Conditions
Liver Cancer
Interventions
BIOLOGICAL

aldesleukin

DRUG

doxorubicin hydrochloride

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00004248 - Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter